The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

Scientists at EPFL and AstraZeneca have developed a method to map the atomic-level structure of amorphous drugs, demonstrated ...

GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.

Recent research shows combining weight loss with blood sugar control is even more effective for reducing health risks ...